INmune Bio Inc. INMB

INMB Company Overview

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and biologic treatments targeting innate immune system dysfunction associated with cancer, neurodegenerative diseases, and chronic inflammation. The company operates within the biotechnology and biopharmaceutical industries, with research programs centered on modulating immune responses through proprietary platforms designed to selectively target pathological inflammatory pathways while preserving normal immune function. Public filings and company disclosures identify its primary development areas as oncology, Alzheimer’s disease, and regenerative medicine.

The company’s principal business lines are built around three technology platforms: DN-TNF, INKmune, and XPro-related therapeutic programs. These platforms are intended to address diseases where chronic inflammation or impaired immune surveillance contributes to disease progression. INmune Bio’s lead assets include therapies aimed at reducing neuroinflammation in Alzheimer’s disease and activating natural killer (NK) cells for cancer treatment. The company was founded in 2015 and is headquartered in the United States. Since inception, it has evolved from an early-stage immunology research company into a multi-platform clinical-stage biotechnology developer pursuing multiple investigational therapies across distinct therapeutic categories.